Pseudomonas aeruginosa bacteraemia: analysis of 262 episodes
Abstract number: r2134
Ezpeleta C., Alava J.A., Unzaga J., Busto C., Gomez E., Atutxa I., Cabezas V., Cisterna R.
The aim of this study is to evaluate the trend in incidence of Pseudomonas aeruginosa bacteraemia (PAB), underlying diseases, source of infection, antibiotic treatment and mortality.
Prospective study of all patients with PAB. Study period Nov 93Jun 05. Blood cultures were performed by means of BACTEC 9240. Te infection control team studies every patient with positive blood cultures. Variables under surveillance are age, sex, underlying illnesses, predisposing conditions, source of bacteremia, nosocomial/community acquired, antibiotic susceptibility, treatment and outcome.
262 episodes, 177 males (67.56%), age 67.17% >60years, Underlying illnesses: Neoplasia 41.92%, Diabetes 16.79%, COPD 12.6%, HIV 8.4%. Hospital acquired 49.62% ranging over time from 38.7% to 57.6%. Source of PAB: Primary 29.0%, Urinary tract 21%%, Respiratory 19.47%, Abdominal 10.31%. Predisposing conditions: mechanical ventilation 8.8%, ICU 9.9%, surgery 13%, urinary catheter 25.19%, antibiotic 42.37%, intravascular catheter 48.5%, immunosuppressive therapy 27.1%, neutropenia: 16.41%. Inappropriate antibiotic therapy 20.23%. Crude mortality 32.06. Time to positivity of blood cultures 80.92% less than 48 h. Polymicrobial bacteremia: 20.23%. Sensitivity to antibiotics: Amikacin 94.7%, Imipenem 90.91%, Ceftazidime 89.02%, Gentamicin 86.74%, and Ciprofloxacin 77.65%. Nosocomial bacteremia: 130 cases, 63.85% males, 56.1% older than 60 y. Underlying illnesses: neoplasia 44.6%, VIH 7.7%. Source of bacteraemia: primary 33%, urinary 20.7%, respiratory 14.6%, catheter related 10%, surgical site 5.3%. Crude mortality nosocomial acquired: 35.66%.
The incidence of PAB in our hospital remained stable over the last 11 years with a peak incidence in 1997 and 2002. Neoplasia was the most common underlying disease. Sensitivity to antibiotics didn't change over time and the most active antibiotics are Amikacin, Imipenem and Ceftazidime.
|Session name:||XXIst ISTH Congress|
|Back to top|